Mr. Leibel's departure, as stated in the company's SEC filing, is not due to any disagreements or disputes with the company's operations or practices. He will continue to serve as an employee until ...

Investing.com -- Jefferies has downgraded its rating on Raspberry Pi Holdings PLC, shifting to a "hold" from a "buy" rating, citing full valuation concerns and ongoing uncertainty in the market, in a ...

Private payrolls increased by 183,000 during the month, according to data from payrolls processor ADP on Wednesday.

Despite these positive outcomes, EyePoint's stock experienced a sharp decline. Cantor Fitzgerald analyst Jennifer Kim commented on the market reaction, stating, "There's nothing here that makes us ...

“RACE beat Q4'24 by +7% and exceeded the 'bar' for its 2025 guide with a >€2.03bn EBIT 'floor'," Barclays (LON: BARC) wrote, adding that some investors remain skeptical about the sustainability of the ...

Investing.com -- Stifel analysts downgraded LVMH (EPA: LVMH) to Hold from Buy on Wednesday, citing limited upside following a ...

The initial market reaction on tariffs decision by the US President Donald Trump saw a spike in the USD and implied FX volatilities at the beginning of the week. However, the situation quickly evolved ...

Investing.com - European business leaders are moving the gauge the impact of possible sweeping tariffs on the European Union ...

The Organization of the Petroleum Exporting Countries (OPEC) saw a decrease in oil output for the second consecutive month in ...

Jefferies has downgraded Marks and Spencer Group (LON: MKS) (M&S) to a 'hold' rating, citing concerns over the UK employment outlook and the stock's valuation nea ...

Wells Fargo downgraded Snap to Equal Weight from Overweight in a note Wednesday, citing rising expenses and slower-than-expected ad revenue growth as the company embarks on a period of heavy ...

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) fell 21% today, diverging from the company's recent announcement of positive results from the Phase 2 VERONA clinical trial of DURAVYU ...